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Abstract
Spontaneous coronary artery dissection (SCAD) has emerged as an important cause of acute 
coronary syndrome, myocardial infarction, and sudden death, particularly among young women 
and individuals with few conventional atherosclerotic risk factors. Patient-initiated research has 
spurred increased awareness of SCAD, and improved diagnostic capabilities and findings from 
large case series have led to changes in approaches to initial and long-term management and 
increasing evidence that SCAD not only is more common than previously believed but also must 
be evaluated and treated differently from atherosclerotic myocardial infarction. High rates of 
recurrent SCAD; its association with female sex, pregnancy, and physical and emotional stress 
triggers; and concurrent systemic arteriopathies, particularly fibromuscular dysplasia, highlight the 
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differences in clinical characteristics of SCAD compared with atherosclerotic disease. Recent 
insights into the causes of, clinical course of, treatment options for, outcomes of, and associated 
conditions of SCAD and the many persistent knowledge gaps are presented.
Keywords
AHA Scientific Statements; coronary artery dissection; spontaneous; fibromuscular dysplasia; 
myocardial infarction; women
Spontaneous coronary artery dissection (SCAD) is defined as an epicardial coronary artery 
dissection that is not associated with atherosclerosis or trauma and not iatrogenic. The 
predominant mechanism of myocardial injury occurring as a result of SCAD is coronary 
artery obstruction caused by formation of an intramural hematoma (IMH) or intimal 
disruption rather than atherosclerotic plaque rupture or intraluminal thrombus. Since the first 
description of SCAD by Pretty1 in 1931 at autopsy, our understanding of it has evolved 
tremendously during the past 8 decades, especially in the past 5 years. On the basis of 
isolated case reports and small series, SCAD was initially described as a rare and almost 
universally fatal cause of acute coronary syndrome (ACS), myocardial infarction (MI), and 
sudden cardiac death in peripartum women,2–4 but contemporary reports have refuted these 
misconceptions. Indeed, advances in our understanding of the epidemiology of SCAD, the 
availability of intravascular imaging techniques,5 the development of SCAD-specific 
angiographic classification,6 heightened awareness among providers, and parallel efforts by 
patients7 using social media to broadly disseminate information suggest that SCAD is far 
more common than previously thought, especially in young women. In addition, SCAD has 
unique risk factors and associated conditions and different diagnostic, therapeutic, and 
prognostic implications compared with atherosclerotic coronary disease.8–17
Despite these advances, dissemination of new knowledge has been slow, and SCAD 
continues to be misdiagnosed, underdiagnosed, and managed as atherosclerotic ACS, which 
may harm patients with SCAD. An emphasis on accurate diagnosis is key to not only 
providing early supportive care but also ensuring that an invasive strategy of percutaneous 
coronary intervention (PCI) be reserved for a select group of these patients because PCI for 
SCAD has been associated with lower technical success and higher complications than PCI 
for atherosclerotic disease.13,18–20 Increasing awareness of SCAD may overcome the limits 
of existing literature, which often excludes sex-specific information, a gap that may have 
clouded the understanding of this underrecognized condition.16,18,20–28
The authors of this statement hope to spur a change in the paradigm of care for women and 
men with SCAD. This American Heart Association scientific statement provides an 
overview of current evidence and expert consensus with the aims of improving the 
understanding and management of SCAD in the medical community and of enhancing 
future collaborations and efforts to elucidate this still relatively poorly understood disease.
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EPIDEMIOLOGY
The true prevalence of SCAD remains uncertain, primarily because it is an underdiagnosed 
condition. Missed diagnoses are driven by a low suspicion of ACS in young women even in 
the presence of classic presenting symptoms, limitations of current coronary angiographic 
techniques, and lack of clinician familiarity with the condition. SCAD most commonly 
occurs in patients with few or no traditional cardiovascular risk factors.8–10,13,16,29 Recent 
series using careful diagnostic criteria that exclude iatrogenic, traumatic, and atherosclerotic 
dissection6 suggest that SCAD may be a cause of up to 1% to 4% of ACS cases 
overall8,30–32 (Table 1), occurs overwhelmingly in women,8,11,13,30,31,33 may be the cause of 
ACS in up to 35% of MIs in women ≤50 years of age,11,16,32 and is the most common cause 
of pregnancy-associated MI (43%)17 (Table 2). Pregnancy-associated SCAD appears to 
make up a smaller proportion of overall SCAD than early case series suggest,13,19,29,33,35 
likely as a result of better detection of less severe SCAD among women who were not 
recently pregnant.
The average age of women with SCAD ranges from 45 to 53 years, but examples of patients 
presenting with SCAD in their second17 through eighth decades of life have been reported.
6,8,11,13,30,31,33,36
 One study reported that men presented with SCAD at a slightly younger 
age than women (mean age, 48.6 [SD, 9.8] years versus 52.3 [SD, 9.2] years; P=0.05).37,38 
Although SCAD has been reported in all major racial and ethnic groups, the majority of 
patients are white, a finding that may reflect referral and sampling bias and the demography 
of patients cared for at reporting centers.8,13,15
The coronary distribution of SCAD has been well described. Although any artery can be 
affected, the left anterior descending artery is the most commonly affected (32%–46% of 
cases).8,10,13,16,19,33 In terms of territories, the left anterior descending and diagonal and 
septal branches are affected in 45% to 61% of cases; the circumflex and ramus and obtuse 
marginal branches in 15% to 45%; the right coronary artery and acute marginal, posterior 
descending, and posterolateral branches in 10% to 39%; and the left main artery in up to 4% 
of cases.10,11,13,16,19,33 In the majority of cases, the mid to distal segments of coronary 
arteries are affected; in only <10% of cases are the proximal left anterior descending or 
circumflex, right coronary, or left main arteries affected.13 Multivessel SCAD occurs in 9% 
to 23% of cases.8,10,11,13,16,19,33,35
HISTOPATHOLOGICAL CLASSIFICATION AND FINDINGS
SCAD is characterized by the spontaneous formation of IMH within the wall of a coronary 
artery (Figure 1). This has been confirmed by both intracoronary imaging39–42 and 
histopathological case reports and series.43–55 More recent publications confirm historical 
reports3,56,57 that describe the separation occurring in the outer third of the tunica media and 
IMH occupying the dissection and compressing the true lumen, leading to coronary 
insufficiency and MI47,50 (Figure 2).
Two theories of how SCAD develops have been described.58 The first theory proposes that 
the primary pathological event is the development of a disruption in the vessel wall (intimal 
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tear), which allows blood from the true lumen to enter and generate a false lumen. The 
second theory proposes that the primary event is a spontaneous hemorrhage arising from the 
vasa vasorum within the vessel wall.59 One group reporting an optical coherence 
tomography series from patients with SCAD noted that an intimal rupture site could not 
always be identified by this type of imaging, a finding supporting the second 
pathophysiological theory in at least a proportion of cases.42,60 For cases in which an intimal 
tear is identified, it remains unclear whether it is the initiating event or whether it is 
attributable to increasing pressure in the false lumen causing reverse intimal rupture into the 
true lumen or to the effect of coronary instrumentation during imaging.
There are several histopathological reports of a peri-adventitial mixed inflammatory 
infiltrate, often with a predominance of eosinophils.44–46,49,50,52,54,55,61 However, there is 
controversy about the pathophysiological significance of this eosinophilic infiltrate. Some 
authors consider it pathognomonic for SCAD,3,54,62 and others attribute it to a nonspecific 
response to vascular injury.50 The presence of an inflammatory cellular infiltrate 
surrounding the dissection may be useful in distinguishing SCAD from iatrogenic 
postmortem dissection, which can confound the diagnosis of true SCAD.50 Cystic medial 
necrosis was reported in a few older series,63–65 but it has either been reported to be 
absent44,49,53 or not commented on in reports since 2005. Fibromuscular dysplasia (FMD) 
involving coronary arteries in which SCAD occurred has been described in several 
histopathological case reports,53,66–68 an implication that coronary FMD was the cause of 
SCAD and in keeping with the recently observed strong association between SCAD and 
FMD.29,69
In addition, the postmortem diagnosis of SCAD may be challenging, and a strong suspicion 
coupled with careful coronary histopathological examination is required in cases of 
unexplained sudden cardiac death.47,50 When SCAD is suspected to be the cause, especially 
in young women, histopathological assessment of the coronary arteries should include distal 
segments of the epicardial arteries because of the predilection of SCAD for middistal 
coronary arteries.15
PATHOGENESIS OF SCAD AND SCAD-ASSOCIATED CONDITIONS
Because of the unique demographic and risk factor profile and the low prevalence of 
traditional cardiovascular risk factors of SCAD,6,8–10,13,16,29 its cause is hypothesized to be 
multifactorial with contributions from underlying arteriopathies, genetic factors, hormonal 
influences, inherited or acquired arteriopathies, or systemic inflammatory diseases, often 
compounded by environmental precipitants or stressors (Table 2).
FMD and Other Systemic Arteriopathies
Of the described arteriopathies, the association of SCAD with multifocal FMD in 
extracoronary arteries has been the most commonly reported. FMD is a non-atherosclerotic, 
noninflammatory vascular disease that can affect nearly any arterial bed and can manifest as 
arterial stenosis, aneurysm, tortuosity, or dissection.70–72 Multifocal FMD is the most 
common type of FMD and is defined angiographically as areas of alternating stenosis and 
dilatation resulting in a string-of-beads pattern (Figure 3). Focal FMD appears 
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angiographically as a single concentric or tubular narrowing; <10% of cases of FMD are of 
this type. FMD is not currently considered a connective tissue disorder, which for the 
purposes of this document refers to conditions in which arterial fragility is genetically 
mediated.
First described in 2005 and subsequently confirmed in several case series, the association of 
SCAD and FMD continues to be an area of considerable interest.69,73 Subsequent cohort 
studies have shown a varying prevalence of concomitant FMD in extracoronary vascular 
beds, ranging from 17% to 86%, depending on the patient population, number of imaged 
vascular beds, and type of imaging used for screening.6,8,13,29,33,34,74,75 There is also 
evidence that the prevalence of SCAD is not insignificant in patients with FMD. In the most 
recent report on dissection and aneurysm in patients with FMD in the US Registry for FMD, 
of the 237 of 921 patients (25.7%) who experienced ≥1 arterial dissections, 25 patients had 
SCAD, representing 10.5% of all dissections and an overall prevalence of coronary 
dissection of 2.7%.76 Case reports of typical histological and angiographic features of FMD 
in coronary arteries, including from patients with a prior SCAD event,53,58,66–68,77–81 have 
led some investigators to hypothesize that SCAD may be a manifestation of coronary FMD 
in at least a proportion of SCAD events.82 Although FMD is the most common 
extracoronary vascular abnormality identified among patients with SCAD, patients without 
imaging signs of FMD have been reported to have other arterial abnormalities, including 
dissections, aneurysms (including intracranial aneurysms in 14%–23%), or extracoronary 
and coronary arterial tortuosity (78%).6,8,13,29,33,74–76,83 Some of these patients may indeed 
have had FMD but it was not identified because of incomplete or insufficiently sensitive 
imaging.
Pregnancy and Female Sex Hormones
The term peripartum SCAD does not have a universal definition, and consistent with recent 
designations, we have elected to use the term pregnancy-associated SCAD.84 Although 
pregnancy-associated SCAD encompasses a relatively small proportion of SCAD cases,
13,19,30,33,84–86
 it is the most common cause of MI among patients who are pregnant or 
postpartum.17 A recent analysis of a US administrative database found a prevalence of 1.81 
SCAD events per 100 000 pregnancies during pregnancy or in the 6-week postpartum 
period.87 The majority of pregnancy-associated SCAD events occur in the third trimester or 
early postpartum period, although SCAD has been reported as early as 5 weeks of gestation 
and up to several months to a year or more postpartum, particularly in women who are still 
lactating.35,85,86,88–90 The left main or left anterior descending artery has been described as 
the most commonly affected.17,35,85,86,89,91,92
The cause of pregnancy-associated SCAD is not fully understood. However, the hormonal 
changes of pregnancy may lead to alterations in the architecture of the arterial wall.
17,84,91,93,94
 One hypothesis suggests that the estrogen and progesterone receptors present in 
the coronary arteries may mediate changes, as they do in other connective tissues, that 
weaken the vessel wall, which culminates in arterial wall rupture, IMH, and onset of clinical 
symptoms.17 Accumulation of these changes over several pregnancies may explain the 
reported heightened risk of SCAD in multiparous women in some12,35,86,88 but not all87 
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series. Demographic and comorbid conditions reported with pregnancy-associated SCAD 
include black race, chronic hypertension, lipid abnormalities, chronic depression, migraines,
86,87
 advanced maternal age and age at first childbirth, and treatment for infertility. 
Gestational hypertension and preeclampsia have variably been associated.86,87 The average 
age at the time of pregnancy-associated SCAD has ranged from 33 to 36 years, a finding 
highlighting the potential impact of older age at time of pregnancy on cardiovascular 
complications such as SCAD.85,86,88,89,95 Because maternal age and multiparity are 
associated, the independent contribution of these factors to SCAD risk is uncertain.
Women with pregnancy-associated SCAD seem to have a poorer prognosis than women with 
SCAD unrelated to pregnancy.85,86,88,89 In a series of 23 women with SCAD, 7 of whom 
had pregnancy-associated SCAD, postpartum patients had larger infarcts, more proximal 
artery dissections (86% versus 19%; P<.004), and lower mean left ventricular (LV) ejection 
fraction (34% versus 49%; P<0.01).85 In the Mayo Clinic SCAD Registry, 54 women with 
pregnancy-associated SCAD were compared with 269 women with non–pregnancy-
associated SCAD. Patients with pregnancy-associated SCAD were younger, were more 
likely to present with ST-segment–elevation MI (50% versus 36%; P=0.013) and left main 
and multivessel dissections, had poorer LV function immediately and at follow-up, and were 
less likely to have concurrent FMD.86 In a recent literature review of 120 pregnancy-
associated SCAD cases by Havakuk et al,96 73% of women were postpartum and 76% 
presented with ST-segment–elevation MI. Maternal complications were common: 
cardiogenic shock in 24%, ventricular fibrillation requiring defibrillation in 16%, 
mechanical support in 28%, and an in-hospital mortality rate of 4%. It is unclear why 
pregnancy-associated SCAD is associated with more aggressive and extensive dissections 
than non–pregnancy-associated SCAD and why the majority of pregnant women are spared 
from pregnancy-associated SCAD.84
Inflammatory Conditions
SCAD is not commonly associated with systemic inflammatory disorders. Laboratory 
evaluation for inflammatory or autoimmune conditions is generally low yield but may be 
considered in the post-MI setting, particularly in patients who have symptoms of or physical 
examination findings of autoimmune or rheumatologic disease. SCAD has been described in 
case reports of patients with various systemic inflammatory diseases, including systemic 
lupus erythematosus,97–102 inflammatory bowel disease,103 polyarteritis nodosa,104 
sarcoidosis,52 celiac disease,105 and cryoglobulinemia in the setting of hepatitis C.106 In 
these series, underlying coronary vasculitis100 or systemic inflammation100 may have 
contributed to the risk of SCAD, and larger cohort studies have shown that at least a small 
proportion of patients have either underlying inflammatory diseases or short-term increases 
in inflammatory markers.13,60 Taken together, these series indicate that underlying 
inflammatory conditions may be predisposing factors in the development of SCAD in a 
small proportion of patients. However, this possibility is based primarily on case reports or 
series of a small number of patients with inflammatory diseases that do not control for the 
prevalence of these conditions in the population reported and may represent coincidental 
association, especially because there is no published pathological proof of causation.
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Inheritance and Genetics
Inherited arteriopathies and connective tissue disorders are infrequently reported as the 
underlying cause for SCAD (≈≤5%).8,13,107 Vascular Ehlers-Danlos syndrome (caused by 
mutations in COL3A1107–109), Marfan syndrome (caused by mutation in FBN1107–110), 
Loeys-Dietz syndrome (caused by mutation in genes encoding members of transforming 
growth factor-β signaling cascade such as TGFBRI, TGFBR2,111 and SMAD3112), and 
other mutations have been implicated and are known to be associated with arterial fragility 
and dissection, resulting in SCAD. Spontaneous arterial dissection without preceding 
aneurysm formation, as occurs in SCAD, is characteristic of vascular Ehlers-Danlos 
syndrome. SCAD has also been described in polycystic kidney disease.113–115
Outside the context of these known genetic conditions, however, SCAD does not seem to be 
strongly familial. In the largest series to investigate family history (421 subjects), Goel et 
al116 documented a family history of SCAD in a very low proportion of patients (1.2%). In 
that study, both dominant and recessive modes of inheritance were suggested, but most 
SCAD cases seem to be sporadic, and no genetic risk loci have yet been definitively 
associated with SCAD. This lack of a consistent inherited genetic pathway appears similar 
to FMD, for which, although heritability has been documented,70,117–120 genetic testing has 
been largely unfruitful because of the absence of an identified monogenetic cause.121,122
Barriers to gene discovery in SCAD are related mostly to the rarity of the condition and its 
predominantly sporadic nature. Sample collection is underway at multiple centers, and 
collaborative efforts will likely be needed to obtain sufficient statistical power to discover 
gene and gene-by-environment associations with SCAD.
Precipitants and Triggers
There appears to be a complex interplay between a vulnerable patient (ie, one with 
underlying arteriopathy) and potential triggers6,8,13,29,38,123–128 (Table 2) that initiate a 
spontaneous arterial tear or IMH. However, this connection is not the case for all patients, 
highlighting the incomplete understanding of the pathophysiology of this disease process. 
Furthermore, although the frequency of patient-reported precipitants of SCAD is relatively 
high compared with that reported in a large multinational cohort of patients with ACS, there 
may be recall bias in the reporting of events around a life-threatening event such as SCAD in 
typically young and previously healthy individuals. Thus, the potential for overreporting is 
important to consider.129
The most commonly reported precipitants are extreme physical or emotional stress. Among 
168 patients at a single center, an extreme emotional (40%) or physical (24%) stressor was 
reported before their SCAD event.13 Emotional stressors have more often been reported as 
precipitants of SCAD in women than in men,38 whereas physical stressors such as intense 
isometric exercise and weight lifting have more often been reported among men with SCAD.
8,38
 Stress cat-echolamine surge during these events has been postulated to lead to coronary 
artery shear stress that, at least in part, contributes to the pathophysiology of SCAD. 
Although this hypothesis has not been specifically tested in patients with SCAD, a similar 
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mechanism was proposed in other stress-induced cardiovascular conditions such as stress-
induced cardiomyopathy (takotsubo syndrome).129,130
Unlike hormonal triggers related to pregnancy, other potential hormone-mediated SCAD 
triggers such as the perimenopausal state, use of oral contraceptives, postmenopausal 
hormone therapy (HT), infertility treatments, and high-dose corticosteroid administration 
have less supportive data, although associations have been reported.6,29,125–127,131 The 
biggest challenge for confirming any of these correlations is that the baseline prevalence of 
these conditions is either common in the general population or unknown.
CLINICAL PRESENTATION
Although there are wide ranges of clinical presentations and severities of SCAD, patients 
who survive and present for initial evaluation almost universally experience ACS and 
increased levels of cardiac enzymes. As many as 2% to 5% of patients present in cardiogenic 
shock.10,11 Among available series of patients presenting for evaluation, 26% to 87% of 
patients with SCAD present with ST-segment–elevation MI, and 13% to 69% present with 
non–ST-segment–elevation MI.10,11,13,16,19,33 Presenting symptoms are consistent with 
atherosclerotic ACS, with chest pain being the most prevalent132 (Figure 4). Ventricular 
arrhythmias or sudden cardiac death account for SCAD presentation in 3% to 11% of 
reported series.8,10,11,13,19 These reports must be interpreted with care because individuals 
whose SCAD is not identified or is misdiagnosed, who do not survive to initial evaluation, or 
in whom coronary imaging or postmortem evaluation is not performed are not included in 
these studies.
Cardiac enzyme levels are almost invariably increased, although the initial troponin level in 
patients with SCAD presenting to the emergency department may be normal.19,133 In a 
cohort of 168 patients with SCAD from Vancouver, all patients had an increased troponin I 
level; the median increase was 6 μg/L (normal, <0.05 μg/L), and the interquartile range was 
broad (0.7–200 μg/L).13 In a Japanese cohort of 63 patients with SCAD, the mean peak 
creatine kinase level (normal, 25–250 IU/L) was lower in young women with SCAD than in 
patients without SCAD (1689 versus 2874 IU/L; P=0.025).11 LV wall motion abnormalities 
detected on echocardiography or early angiography were common, but overall LV ejection 
fraction was often preserved.19,134
DIAGNOSIS
Patients with SCAD are at risk of receiving alternative diagnoses and of being discharged 
after emergency department evaluation because their relatively young age and absence of 
atherosclerotic risk factors frequently do not fit the expected phenotype of an atherosclerotic 
patient with MI. Accurate diagnosis of SCAD in the early stages of ACS presentation is 
important because management and investigation are different from those for atherosclerotic 
forms of coronary artery disease.12,19 The suspicion for SCAD is typically instigated by 
clinical presenting features such as patient demographics, especially young age, female sex, 
and few or no conventional cardiovascular risk factors. Once SCAD is suspected, coronary 
angiography should be performed as early as feasible, especially in the setting of ST-
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segment–elevation MI. Despite the inherent limitations of conventional coronary 
angiography that reduce the diagnostic capability for SCAD, this technique remains the first-
line diagnostic imaging method because it is widely available and recommended for early 
invasive management of ACS.135 The key limiting factor is that angiography is 2-
dimensional “lumenography” and does not specifically image the arterial wall.
Dedicated intracoronary imaging methods, including intravascular ultrasonography and 
optical coherence tomography, provide detailed visualization of the arterial wall that aids the 
diagnosis of SCAD. However, these tools have additional risks and costs, and they are not 
readily available in all catheterization laboratories. Thus, availability, competence, and 
expertise can vary widely with these technologies. As a consequence, conventional coronary 
angiography remains instrumental in diagnosing SCAD, and cardiologists should become 
pro-ficient at recognizing its various angiographic patterns.
Coronary Angiography
The traditional angiographic description of SCAD emphasized the presence of multiple 
radiolucent lumens and extraluminal contrast staining, which may have included spiral 
dissection or intraluminal filling defects.136 However, contemporary angiographic SCAD 
series have since shown that this “pathognomonic” appearance is present in only a small 
proportion of SCAD cases.6,41 Addressing the drawbacks of prior descriptions, a specific 
SCAD angiographic classification was proposed and now has been commonly adopted.6 In 
the Saw angiographic SCAD classification, type 1 refers to the classic appearance of 
multiple radiolucent lumens or arterial wall contrast staining (Figure 5A). Type 2 refers to 
the presence of diffuse stenosis that can be of varying severity and length (usually >20 mm; 
Figure 5B): Variant 2A is diffuse arterial narrowing bordered by normal segments proximal 
and distal to the IMH, and variant 2B is diffuse narrowing that extends to the distal tip of the 
artery.58 Type 3 is focal or tubular stenosis, usually <20 mm in length, that mimics 
atherosclerosis (Figure 5C); intracoronary imaging is required to confirm the presence of 
IMH and to diagnose SCAD (Figure 5D).
Several studies have reported that the diffuse smooth stenosis pattern (ie, type 2) is the most 
common angiographic manifestation of SCAD,11,13,16,41 occurring in up to 67.5% of 
dissected arteries, followed by type 1 in 29.1% and type 3 in 3.4%.13 Thus, reliance solely 
on the traditional multiple lumens or contrast staining of arterial walls to diagnose SCAD 
would result in missed diagnoses of >70% of SCAD cases. Therefore, familiarity with the 
diffuse narrowed-lumen appearance of IMH and use of intracoronary imaging are important 
steps to improve the diagnosis of SCAD. Care must be taken to ensure that SCAD is not 
misinterpreted as normal coronaries, atherosclerotic disease, coronary vasospasm, 
thromboembolism, or takotsubo syndrome.137,138
Although coronary angiography is the standard for the diagnosis of SCAD, this invasive 
procedure has intrinsic risk. Iatrogenic catheter-induced coronary artery dissection is 
reported to be increased in patients with SCAD; the reported overall prevalence is 3.4%,
139,140
 whereas it is <0.2% for standard coronary angiography.139,140 Underlying arterial 
fragility in patients with SCAD is believed to accentuate the risks for iatrogenic dissection.
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Intracoronary Imaging
Intracoronary imaging has become instrumental to aid the diagnosis of SCAD in 
angiographically subtle or non-diagnostic cases. Fortunately, the need to use intracoronary 
imaging has diminished in recent years because of improved SCAD-pattern recognition on 
coronary angiography. Intravascular ultrasonography has been available for >20 years, and it 
offers good spatial resolution of ≈150 μm to image the coronary arterial wall. It can detect 
intimal tear, false lumen, IMH, and intraluminal thrombi, although its resolution may not be 
adequate to clearly identify all such abnormalities related to SCAD.42,141 It has the 
advantage of deep penetration to assess the depth and extent of IMH. Optical coherence 
tomography is a more advanced technology that uses light waves to image the arterial wall. 
This technology has revolutionized the diagnosis of SCAD since its first reported use in 
2008.5,13,34,40,41,69 It has a spatial resolution of 10 to 20 μm, and thus, it is superior to 
intravascular ultrasonography for delineating the lumen-intimal interface and is better for 
visualizing intimal tears, false lumen, IMH, and intraluminal thrombi (Figure 6). This 
superior imaging improves the ease of detecting SCAD and is the preferred intracoronary 
imaging method when angiographic diagnosis is uncertain and when it is believed that 
intravascular imaging can be safely undertaken.12 Nevertheless, both optical coherence 
tomography and intravascular ultrasonography can provide complementary details for 
diagnosis of SCAD, which on intracoronary imaging requires the presence of IMH or double 
lumen.60 Because not all laboratories have both technologies accessible, angiographers 
should become familiar with interpreting features of SCAD with their available 
intracoronary imaging method.
Despite the importance of intracoronary imaging for the diagnosis of SCAD, these tools 
have potential risks, including extending the coronary dissection with wire or imaging 
catheter, guide-catheter iatrogenic dissection,139 catheter-induced occlusion of true lumen, 
and hydraulic extension with contrast injection for optical coherence tomography. With 
weighing of the risks and benefits, intracoronary imaging should be pursued only when 
coronary angiographic diagnosis is uncertain (eg, type 3 or unclear lesions) and when the 
vessel diameter is large enough for intracoronary imaging. In addition, there is generally no 
clinical indication to evaluate the full depth and extent of IMH or false lumen because 
conservative management is typically preferred. Therefore, intracoronary imaging can be 
limited to the proximal segment of dissection without the need to image the entire dissected 
segment. An algorithm for the angiographic diagnosis of SCAD is presented in Figure 7.
Coronary Computed Tomography Angiography
Cardiac computed tomography angiography (CCTA) of the coronary arteries is emerging as 
an efficient tool for coronary assessment in low- and intermediate-risk patients presenting 
with ACS.142–146 Although the role of CCTA in patients with uncertain ACS diagnoses is 
promising, no dedicated study has addressed CCTA in the setting of acute SCAD. CCTA is 
generally contraindicated in patients presenting with high-risk ACS and is not recommended 
as the first-line investigation for suspected acute SCAD.143,147,148 Moreover, normal results 
on CCTA do not exclude SCAD. Coronary dissection seen on retrospective evaluation of 
initially negative CCTA images after SCAD was angiographically proved149 reinforces the 
need for CCTA or “triple rule-out” protocols that include CCTA to be interpreted with great 
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caution when SCAD is in the differential diagnosis as a means to minimize false-negative 
results.147,148
Shortcomings of CCTA for SCAD include lower spatial and temporal resolution than 
coronary angiography,150 inclusion of patients with a low pretest probability for 
atherosclerotic coronary artery disease that thereby possibly affects the interpreters’ 
judgment, and a SCAD coronary appearance on CCTA that differs from that of typical 
atherosclerosis.149,151 Coronary atherosclerosis on CCTA commonly appears as discrete 
calcifications or focal dense, noncalcified plaques, whereas SCAD vessels may appear as 
having dual lumens on CCTA with contrast agent in the dissected plane. Most commonly, 
however, SCAD occurs without intimal disruption such that the contrast agent does not 
opacify the false lumen.58 Although in such cases the coronary artery narrowing and IMH 
are sometimes visualized on CCTA, these unique features can be challenging to recognize or 
are unidentifiable in small vessels.58,149,151 Poorly gated or nongated computed tomography 
angiography (such as computed tomography for pulmonary embolus) is inadequate for 
coronary artery assessment.53,149,152,153
CCTA may be useful for noninvasive follow-up of patients with SCAD, particularly in those 
with dissections in proximal or large-caliber coronary arteries.151,154,155 A study of 24 
patients with SCAD who had follow-up CCTA found it to be a valuable, noninvasive study 
without complications and identified healing in most (83%).155 SCAD involvement of distal 
coronary arteries or side branches, or of vessel caliber <2.5 mm, generally is not well 
visualized on CCTA; therefore, this method is of limited value in many SCAD cases.6,13
INITIAL MANAGEMENT
The American College of Cardiology/American Heart Association and the European Society 
of Cardiology guidelines for the management of ACS advocate an early invasive strategy 
with revascularization of culprit lesions over conservative therapy alone.156,157 This stent-
based lesion pacification reduces the risk of recurrent occlusion at the lesion site and 
associated adverse events in atherosclerotic MI, but there have been no randomized studies 
or subgroup analyses of treatment outcomes or comparisons between acute revascularization 
strategies for ACS caused by SCAD. These studies are critical because the mechanism of 
vessel obstruction, the acute vessel response to balloon dilation, and the natural history of 
conservatively managed lesions differ significantly in SCAD compared with atherosclerotic 
ACS.
Conservative Management
No comprehensive prospective studies have routinely performed angiographic restudy after 
SCAD, but observational data have indicated angiographic “healing” of SCAD lesions in the 
majority of patients (70%–97%) who were selectively restudied weeks to months after a 
conservatively managed index episode.6,8,16,19,33,41 A minority of patients had persistent 
dissection on angiography,8,13,19 and it is unclear why dissection persisted in these cases or 
whether very late healing may have occurred subsequently. The time course of healing 
remains uncertain, but it can be detected within days8,13,158 and is frequently observed by 1 
month.8,13 In an observational study of 131 SCAD lesions that had repeat coronary 
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angiography, spontaneous healing occurred in 88.5% of cases. For the cases in which repeat 
angiography was performed early (<35 days from index event), there were residual 
dissections. However, repeat angiography performed after 35 days showed angiographic 
healing in all cases.139 These results suggest a time dependency for healing to occur.
Of note, early complications of recurrent MI may develop in 5% to 10% of conservatively 
managed patients, mostly related to extension of dissection within the first 7 days after an 
acute episode.8,10,13 The majority of these patients require emergency revascularization, and 
no angiographic or clinical predictors of acute worsening have been identified. Because of 
these findings, inpatient monitoring for an extended period is typically recommended as part 
of a conservative strategy for SCAD management.12,19,159 Conservative therapy may not be 
appropriate in high-risk patients with ongoing ischemia, left main artery dissection, or 
hemodynamic instability. In such cases, it is the consensus of the working group that urgent 
intervention with PCI or coronary artery bypass grafting (CABG) should be considered, but 
such decisions should be individualized and contemplated in the context of the coronary 
anatomy and the expertise of the operators or centers. A proposed algorithm to guide 
conservative versus invasive management is outlined in Figure 8.
Percutaneous Coronary Intervention
Observational studies have shown consistently that PCI for the treatment of SCAD is 
associated with an increased risk of complications8–11,13,16,19,33 and suboptimal outcomes. 
Affected coronary arteries may be inherently weak architecturally as a result of underlying 
arteriopathies, which can render them more susceptible to iatrogenic dissections and 
extension of dissections with PCI. Coronary guidewires may enter the false lumen and 
occlude the true lumen. Balloon dilation and stent placement can also confer risks of 
extending dissection of the intima or propagating IMH upstream and downstream from the 
vessel, causing worsening of vessel obstruction. Such extensions of dissection can be 
clinically significant, with some resulting in spiral dissections to the distal arterial segments 
or retrograde dissection into proximal arteries and adjacent branches, including the left main 
coronary artery. Given that dissection lengths are often extensive, complete PCI may require 
long coronary stents, which can increase the risk of subsequent instent restenosis and stent 
thrombosis. In addition, SCAD most frequently affects the distal coronary segments, which 
may be too small or too distal for stent implantation. Moreover, IMH naturally resorbs over 
time, which can result in subacute and late stent strut malapposition, potentially 
predisposing to future risk of stent thrombosis.158,159
These technical complications have been associated with adverse clinical outcomes in 
several series. The Mayo Clinic series of 189 patients showed PCI technical failure in 53% 
of the patients initially managed with PCI.19 Even when the percentage of residual stenosis 
was ignored as a parameter, technical failure occurred in 30%. Emergency CABG was 
required in 13% of those treated with primary PCI; emergency repeat PCI was required in 
4%; and there was 1 death. Similar rates of adverse technical and clinical outcomes occurred 
whether there was impaired flow or normal or near-normal vessel flow at baseline.19 In the 
Vancouver cohort of 168 patients, technical failure occurred in 36%, stent thrombosis in 6%, 
and emergency CABG as a complication of PCI in 12%.13 Similarly, in a European study of 
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134 patients, 27% of PCIs resulted in technical failure, and 9% of patients required 
emergency CABG.10
Optimizing PCI Approaches
Improving the outcomes of PCI in SCAD requires meticulous angiographic and 
instrumentation techniques, including avoidance of deep catheter engagement, noncoaxial 
positioning of catheter tip, catheter dampening, and strong contrast agent injection. In 
addition, in potential SCAD cases, preferential use of femoral access or extra caution with 
radial catheterization should be considered in light of a retrospective series in which there 
was a 3-fold higher risk for catheter-induced iat-rogenic dissection in patients with SCAD 
undergoing coronary angiography when radial access was used as opposed to femoral 
access.13,139
Multiple interventional strategies have been described when PCI is pursued for SCAD 
lesions; however, no comparative studies have assessed the superiority of such techniques. 
Examples of approaches that have had successful outcomes include the following: (1) 
implantation of long drug-eluting stents covering in excess of 5 to 10 mm on both proximal 
and distal edges of the IMH so as to accommodate propagation of the IMH when 
compressed by the stent; (2) direct stenting without balloon predilation to avoid additional 
risks of extension of the IMH; (3) balloon angioplasty alone to restore coronary flow without 
stenting; (4) cutting balloon fenestration of the IMH to allow decompression of the false 
lumen blood pool into the true lumen160,161 with or without additional stenting 
(acknowledging the theoretical risk of coronary rupture, cutting balloon inflation should be 
performed cautiously with an undersized balloon); (5) multistent approach by sealing distal 
and proximal ends first with stents, before stenting the middle, to minimize IMH 
propagation162; and (6) use of bioresorbable stents to provide a temporary scaffold because 
complete resorption of struts occurs within 2 years.158,163 Finally, after successful PCI, dual-
antiplatelet therapy should be administered according to the stents implanted.158,164,165
Coronary Artery Bypass Grafting
Published evidence on CABG after SCAD is limited to case reports, small case series, and 
retrospective observational studies with small sample size. CABG has been described as a 
treatment strategy for SCAD in patients with left main stem or proximal dissections, after 
technical failure of attempted PCI, when there is a complication of attempted PCI, and when 
ischemia is refractory despite attempted conservative therapy. Use of arterial and venous 
bypass conduits has been described, as have off-pump and robotic approaches.166–168 One 
study reported high rates of initial technical success and inhospital clinical outcomes with 
CABG as an index treatment strategy (n=20 patients, 32 conduits).19 Although these 
findings provide some reassurance for CABG as a viable revascularization option for acute 
SCAD, caution should be used in the overinterpretation of the data given the almost certain 
selection bias for patients deemed to have suitable anatomy. During long-term follow-up, 1 
study reported a high rate of both venous and arterial conduit failure (11 of 16 graft failures 
from 11 of 20 patients undergoing follow-up angiography), almost certainly the result of 
subsequent healing of native SCAD vessels and competitive flow promoting graft occlusion. 
The study also showed that CABG was not protective against recurrent SCAD events.19 The 
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use of vein grafts may be considered in light of frequent late graft failure and the opportunity 
to preserve arterial conduits for the future.
In summary, on the basis of the retrospective observational data cited above, conservative 
therapy is generally the preferred strategy in patients with SCAD who are clinically stable 
and without objective evidence of ongoing ischemia and has generally been associated with 
favorable outcomes.9,19 A conservative strategy is additionally appropriate in patients with 
occluded distal vessels or distal branches that would not routinely be amenable to PCI.
EARLY SCAD OUTCOMES: IMPLICATIONS FOR DURATION OF 
HOSPITALIZATION
Although rates of in-hospital mortality are low, up to 14% of patients require urgent in-
hospital revascularization, usually because of extension of dissection. Recognized 
complications of SCAD depend on the initial treatment strategy (Table 3). Acknowledging 
the biases associated with selected retrospective series, among reports including >100 
patients,10,13,19 49.7% to 89.7% received medical therapy as initial treatment, and 2.6% to 
8.5% of conservatively treated patients eventually required revascularization during the 
index hospitalization. Revascularization with PCI was the initial treatment for SCAD in 
16.7% to 47.1% of patients. Reported PCI success rates varied (36.4%–72.5%), most likely 
because of the wide variability in the definition of PCI success in SCAD, but all were 
substantially lower than success rates reported in control subjects with atherosclerotic ACS. 
Emergency CABG was required in 2.2% to 7.4% of patients who initially received medical 
therapy or PCI. An initial CABG revascularization approach was used in 0.6% to 3.7%, and 
initial success (87.5%–100%) was high in this small group of patients.
In current clinical practice, the duration of hospitalization after ACS is therefore largely 
dictated by the management strategy for the patient and the ongoing symptoms.172 All 
patients with acute MI caused by SCAD are typically admitted for a minimum of 48 hours to 
allow adjustment of medications and in-hospital evaluation of physical activity tolerance 
before discharge.12 A prolonged period of in-hospital monitoring (3–5 days) is justified as 
part of a conservative strategy to observe for a small but important (5%–10%) early hazard 
of dissection extension or new recurrent SCAD.13,19 If clinical worsening occurs despite 
conservative management (worsening of symptoms together with evidence of ischemia by 
electrocardiography or significant arrhythmia), repeat angiography should be performed and 
emergency revascularization undertaken to relieve ischemia if feasible. Chest pain does not 
necessarily imply active myocardial ischemia. Chest pain may be a manifestation of vessel 
wall dissection itself. Thus, chest pain alone should not be an indication to pursue 
emergency revascularization, especially if there is no evidence of ischemia or if the vessel 
flow is normal. Patients in whom PCI is unsuccessful or complicated by extension of 
dissection, ongoing ischemia, ventricular arrhythmias, or heart failure often require longer 
hospitalizations, similar to conservatively treated patients.
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OTHER SUPPORTIVE THERAPIES
Data on the use of therapies supportive of LV function or for persistent ischemia in SCAD 
are limited to single-patient case reports, each with a favorable outcome. Intra-aortic balloon 
pump counterpulsation has been used mostly to support surgical revascularization or 
sometimes to bridge pregnant patients through surgical delivery before CABG.173–181 LV 
assist devices or extracorporeal membrane oxygenation has been used as a bridge to 
transplantation or to support recovery after CABG.175,177,180,182–186 In 1 case, 
extracorporeal membrane oxygenation was used for cardiogenic shock after SCAD-
associated cardiac arrest treated with PCI and was a successful bridge to myocardial 
recovery.180 The favorable outcomes in all reported cases likely represent a reporting bias 
given the high-risk scenarios described. The theoretical risks of percutaneous support 
devices in the setting of SCAD compared with atherosclerotic ACS include an increased 
propensity for iliac or femoral arterial dissection with the placement of large-bore catheters 
in the presence of FMD or other arteriopathies and hydraulic extension of intimal coronary 
dissection with increased diastolic coronary flow during intra-aortic balloon pump 
counterpulsation. Therapies supportive of LV function can be considered in cases of 
cardiogenic shock after SCAD as a bridge to recovery or transplantation. No data are 
available to support unique strategies in SCAD that differ from current consensus 
recommendations in this area.187
The role of implantable cardioverter-defibrillators or use of external defibrillator vests in 
patients with SCAD who present with sudden cardiac arrest temporally related to their 
ischemic event has not been studied. Patients with SCAD have been reported to receive early 
implantation of cardioverter-defibrillators or more aggressive management despite the 
absence of high-risk features such as recurrent arrhythmia, LV dysfunction, or persistent 
ischemia.188 There are potential harms with this unproven aggressive practice, and currently, 
there is insufficient evidence to suggest altering clinical decision making for implantation of 
cardioverter-defibrillators on the basis of the cause of the ischemic event.172,189
MEDICAL THERAPY
The ultimate goals of short- and long-term medical therapy of SCAD are to alleviate 
symptoms, to improve short- and long-term outcomes, and to prevent recurrent SCAD. 
Unfortunately, there is a substantial gap in evidence to guide clinicians in this regard because 
of the relatively recent recognition of SCAD as an important clinical entity and the absence 
of identified cellular and molecular targets or randomized controlled trials to support an 
evidence-based approach. Given the paucity of evidence currently available, the following 
approaches are based largely on expert opinions derived from the clinical experience of 
members of the writing group.
Anticoagulation and Antiplatelet Therapy
Because the pathophysiology, mechanisms of ischemia, PCI outcomes, and residua of 
SCAD are distinct from those associated with atherosclerotic ACS, many investigators have 
questioned the rationale and potential risks of using standard ACS therapies in patients with 
SCAD. For instance, early heparin use may provide benefit by reducing thrombus burden, 
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but there are theoretical concerns about its use in the setting of acute SCAD presentation 
related to accentuating the risk of bleeding into the IMH or extension of dissection. 
Therefore, if systemic anticoagulation is started at hospital presentation, in the absence of 
other indications for systemic anticoagulation, consideration of discontinuation is 
appropriate once SCAD is diagnosed.190
Similarly, there are no data to guide the use of glycoprotein IIb/IIIa inhibitors in the 
emergency management of SCAD. Theoretical concerns about the extension of dissection, 
additional bleeding risk, and absence of evidence of benefit suggest a cautious approach to 
their use.190
Patients with SCAD who are undergoing coronary revascularization should receive the 
standard guideline-based antiplatelet therapy after PCI.156 Clear evidence supporting the use 
of dual-antiplatelet therapy in patients with SCAD who do not undergo coronary 
intervention is lacking. Although theoretical benefits of early dual-antiplatelet therapy in 
SCAD include protection from additional thrombosis in the prothrombotic environment 
caused by intimal dissection, many practitioners avoid its use in light of an increased 
bleeding risk and no evidence of benefit. No study has compared short- or long-term 
outcomes or bleeding risks related to the use of dual-antiplatelet therapy and aspirin alone in 
SCAD.
In adherence with current guideline-directed use of antiplatelet therapy after ACS, some 
experts recommend dual-antiplatelet therapy for at least 1 year after SCAD, regardless of 
initial management strategy, along with lifelong aspirin use.156 Others opt for no or limited 
use (1–3 months) followed by longer-term aspirin therapy. A retrospective Italian series 
examining in-hospital and long-term clinical outcomes among patients with SCAD found 
that dual-antiplatelet therapy with predominantly clopidogrel was administered to 82% of 
conservatively managed patients and 94% of patients who underwent PCI.10 This therapy 
was continued for a mean of 12.4 months (SD, 7.8 months) in patients who had stenting and 
for 10.9 months (SD, 2.9 months) in those treated conservatively. Bleeding complications 
were not reported, but long-term outcomes in both groups were similar.10
Most experts recommend aspirin use for at least 1 year and frequently indefinitely after 
SCAD in patients who receive medical treatment, in the absence of contraindications.
10,31,190,191
 In light of increased bleeding risks with antiplatelet agents, especially 
menorrhagia in premenopausal women, and uncertain benefits and risks, individual selection 
of suitability for dual-anti-platelet therapy and aspirin therapy in conservatively managed 
survivors of SCAD is indicated.
β-Adrenergic Blockers
β-Blockers should be considered in patients with SCAD who have LV dysfunction or 
arrhythmias and for management of hypertension. Some experts advocate for their routine 
use for SCAD12 on the basis of extrapolation from benefits in atherosclerotic MI135 or aortic 
dissection,192 whereas others recommend that they be used selectively out of concern for 
exacerbating vasospasm or symptomatic hypotension. In practice, β-blocker use is often 
limited by adverse effects, especially symptoms of fatigue and hypotension. However, in a 
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recently reported 327-patient series from Vancouver with a median duration of follow-up of 
3.1 years, the use of β-blockers was associated with a hazard ratio of 0.36 for recurrent 
SCAD in multivariable analysis,193 a finding strengthening the practice of β-blocker 
administration after SCAD.
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
After SCAD, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 
should be used when MI is complicated by LV systolic dysfunction, according to national 
guidelines for the management of patients after MI.135 These drugs are also a treatment 
option for concomitant hypertension. Female patients of reproductive age must be warned of 
the teratogenicity of renin-angiotensin system antagonists.
Statins
In a retrospective cohort of 87 patients, no relationship was found between post-SCAD 
medical management at discharge and SCAD recurrence, with the exception of statin use. 
Statin use was higher in patients who had a SCAD recurrence; however, this finding may 
have been affected by sample size, date of index event, and medication use that was started 
after discharge.8 In a more recent 327-patient SCAD cohort, no association was found 
between statin use and recurrent SCAD.193 Statin therapy is therefore not recommended 
routinely after SCAD but is reserved for patients meeting guideline-based indications for 
primary prevention of atherosclerosis194 and for the management of patients with 
established concomitant atherosclerotic disease or diabetes mellitus.194
Antianginal Therapy
The predominant role of antianginal therapies is for post-SCAD chest pain syndromes (see 
Evaluation and Management of Chest Pain Syndromes After SCAD). Inpatient management 
of chest pain may warrant antianginal therapy, but currently, there is not a role for the 
routine use of antianginal therapy for either the index SCAD hospitalization or long term. 
Chest discomfort is common in outpatients after SCAD, and for patients who are not 
candidates for revascularization or who have evidence suggesting coronary vasospasm or 
coronary microvascular dysfunction, relief of ischemia and symptoms may be achieved with 
nitrates, calcium channel blockers, or ranolazine. Their use, however, must be balanced with 
their adverse effect profile, most commonly symptomatic hypotension and headache 
(nitrates).
PREGNANCY-ASSOCIATED SCAD: DIAGNOSIS AND SHORT-TERM 
MANAGEMENT
The majority of pregnancy-associated SCADs occur in the first 4 weeks after delivery, but 
SCAD has been reported during virtually all stages of pregnancy.86,96 Management of 
SCAD in the pregnant or peripartum patient requires a multidisciplinary team 
approach195,196 from cardiology and obstetric services that incorporates management for the 
mother in combination with considerations for fetal well-being. Recommendations for 
pregnancy follow-up and delivery after SCAD have been reviewed elsewhere and depend on 
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both maternal and fetal status with the goals of limiting maternal hemodynamic demand and 
close fetal monitoring.90 However, despite the special situation presented by pregnancy, the 
principles of SCAD management are largely the same as for non–pregnancy-associated 
SCAD, namely maintenance of a strong suspicion to ensure that the diagnosis is not missed, 
early and careful angiography to avoid iatrogenic dissection196,197 and to confirm the 
diagnosis (fetal radiation exposure is relatively low with current techniques90,198,199), and 
aiming for conservative management if there is no evidence of ongoing ischemia or 
infarction, hemodynamic instability, or particularly high-risk anatomy.17,200
Special consideration must be given to post-SCAD pharmacotherapy recommendations for 
women who are pregnant or lactating. Given the unclear usefulness of clopidogrel therapy in 
SCAD, its use during pregnancy by women who do not undergo PCI should be 
individualized.201 There are no clear safety data for clopidogrel use during pregnancy or 
breastfeeding, and although there are case reports of it being used safely,202–204 it is 
generally not recommended in women who are breastfeeding.205,206 Low-dose aspirin use is 
safe during pregnancy and breastfeeding.195
Although β-blockers are associated with fetal growth restriction, they are routinely used 
during pregnancy for the treatment of hypertension. Labetalol is the preferred agent, 
especially in early pregnancy, because both metoprolol and atenolol are more highly 
associated with lower placental and fetal weights at delivery.195,207 Atenolol has also been 
associated with bradycardia in breastfed infants; therefore, it should also be avoided during 
breastfeeding.206,208
CARDIAC REHABILITATION, PHYSICAL ACTIVITY, AND PSYCHOSOCIAL 
CONSIDERATIONS AFTER SCAD
Cardiac Rehabilitation
All patients who have MI caused by SCAD should be referred for cardiac rehabilitation209 
consistent with the secondary prevention, risk reduction, and psychosocial support strategy 
recommendations.27,156,210,211 The program should be tailored and individualized, taking 
into account not only cardiopulmonary factors such as ejection fraction but also patient age, 
pre-SCAD physical activity level, and patient-centered recovery goals.211,212 Current 
evidence in the SCAD population suggests low rates of both referral to and participation in 
cardiac rehabilitation209,213,214 despite clear evidence of both safety and benefit, including 
improved measures of physical and psychosocial well-being, improved metabolic 
parameters, and lower symptom frequency.213–221 These low rates are compounded by the 
lower overall referral of women to cardiac rehabilitation,216,222 healthcare providers’ 
reluctance to refer patients with SCAD for cardiac rehabilitation because of fears that 
physical exertion will trigger recurrent SCAD, or the belief that relatively fit young patients 
without atherosclerotic heart disease may not benefit from cardiac rehabilitation.215 Patients 
with SCAD who enroll in cardiac rehabilitation often do not complete the program213,214 
and may face barriers to participation unique to young women such as caregiving and work 
responsibilities, travel concerns, cost, and ongoing symptoms.214,222
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Physical Activity During and After Cardiac Rehabilitation
In light of the association with physical activity as a trigger for SCAD, concern exists about 
the safety of various forms of physical activity and exercise after SCAD.13,223 As a result, 
and with the potential for physical and mental harm, some patients with SCAD continue to 
receive advice to severely restrict their activities such as to avoid lifting >10 lb or not to 
pursue activity beyond limited walking,220 which could place them at the risks associated 
with a sedentary lifestyle. Many patients had high levels of physical activity before their first 
SCAD event and express high levels of motivation to resume those activities.214 Therefore, 
providers are encouraged to prescribe a prudent approach to physical activity, balancing 
known benefits of exercise with the potential risks associated with high levels of exertion 
and strain. Referral to and participation in cardiac rehabilitation are paramount for 
addressing exercise-induced symptoms, providing immediate feedback on exercise 
hemodynamics, and individualizing fitness needs.
Although patients and providers want specific guidelines for or limits to physical activity, in 
the absence of evidence for benefit or harm, arbitrary heart rate and weight lifting limits can 
sometimes lead to frustration or fear with unclear benefit both during and after cardiac 
rehabilitation participation. Clinicians may want to consider conservative thresholds for a 
cardiac rehabilitation entrance exercise treadmill test that mirror those of the Vancouver 
General Hospital SCAD Program (blood pressure no higher than 130/80 mm Hg; heart rate 
50% to 70% of heart rate reserve; free weights for resistance training of 2 to 12 lb, starting 
low and gradually increasing).214
Weight training with resistance up to 20 lb for women and 50 lb for men was shown to be 
safe in a small SCAD cardiac rehabilitation series.214,220 Strength training recommendations 
are typically to use low resistance and high repetitions designed to avoid strain or Valsalva 
maneuver. Cardiopulmonary stress testing after cardiac rehabilitation has been used by some 
groups as a way of developing more precise and individualized parameters based on level of 
fitness. This allows the development of parameters that avoid exercising near or above the 
anaerobic threshold and for detection of exercise-induced hypertension.192,220,224
In the absence of evidence for benefit or harm, such heart rate and weight lifting limits 
remain arbitrary, and larger prospective studies are needed to confirm comparison with 
standard cardiac rehabilitation programs or the safety of higher physical activity thresholds.
209,225
 Current practice is based largely on clinical experience214,220 and recommendations 
offered to patients with aortic dilatation or aortopathy,192,226 recognizing the substantial 
differences in exercise-induced hemodynamics within the aorta and coronary arteries. In 
addition to any symptom-limited physical activity guidelines, patients with SCAD should 
generally be advised to avoid prolonged high-intensity activities, highly competitive or 
contact sports, activities performed to exhaustion (racing, boot camp), abrupt increases in 
physical activity without a warm-up, exercise in extremes of temperature (hot yoga, cold 
weather) or terrain, or performance of Valsalva maneuver during lifting or exercise.
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Psychosocial Considerations
Addressing mental health is a critical component of improving the short- and long-term 
health of patients with SCAD. The psychosocial effects of a diagnosis of heart disease are 
substantial, but patients with SCAD are a particularly high-risk population given that they 
are predominantly younger women who have received a diagnosis with substantial 
uncertainty in terms of management and prognosis. Anxiety and depression are common 
among survivors of SCAD, especially in those whose SCAD occurred during the peripartum 
period.225 In a recent cross-sectional study of 158 patients with SCAD, ≈40% reported a 
history of depression and anxiety at any point in their life, and about one third reported 
receiving medication or behavioral therapy for their anxiety and depression after their initial 
SCAD.225 Baseline characteristics of patients with SCAD who participated in cardiac 
rehabilitation showed that approximately one fifth214 to one third29 of patients reported a 
history of depression. Compared with patients with non-SCAD MI, patients with SCAD MI 
have higher psychological distress, depression and worry, anxiety, and tension scores on 
psychosocial questionnaires.221
Patients with SCAD are an already high-risk group for psychological morbidity. Among all 
patients with prior MI, younger women are at high risk for post-MI chest pain syndromes 
compared with men and older women. They experience short- and long-term 
outcomes20,227,228; angina229–231; psychosocial risk factors, including depression, anxiety, 
and posttraumatic stress disorder; increased prevalence of stress or depression at the time of 
MI230,232; more caregiving responsibilities233; lower health-related quality of life229,230; and 
reduced physical and mental functioning after discharge.20,227–231,234 Current guidelines 
recommend formal screening for depression and anxiety after MI,235 but younger and 
female patients often do not receive these services.222
Patients with SCAD also face unique issues. They are more often treated by a healthcare 
team that has little familiarity with their condition or who voice uncertainty about the 
diagnosis or treatment. They may be repeatedly advised to “change their lifestyle” as if they 
had atherosclerosis, despite the absence of modifiable cardiovascular disease risk factors. 
The lack of effective secondary prevention options can be anxiety provoking. Postpartum 
patients have the additional burden of caregiving, hormonal shifts, peripartum mood 
disorders, and disruption of expectations of early bonding with their infant or breastfeeding. 
Most survivors of SCAD are fearful of resuming physical activities in light of the possibility 
of triggering another dissection. The relatively uncommon nature of SCAD often results in a 
lack of peer support. In addition, the medical jargon inundating patients with newly 
diagnosed SCAD can often be intimidating; therefore, patient-focused medical literature 
such as a “patient page” describing SCAD in lay terms can be helpful.236
Online communities and virtual peer support are especially important because patients may 
be geographically separated from each other. The first SCAD-related international support 
community was hosted by WomenHeart: The National Coalition for Women With Heart 
Disease.237 Additional SCAD-specific patient support, advocacy, and nonprofit groups have 
formed around the world to raise awareness of SCAD, to connect patients, and to 
disseminate clinical practice and research developments. These organizations include SCAD 
Alliance,238 Beat SCAD,239 and SCAD Research, Inc.240 In addition, numerous patient-
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initiated online communities have emerged on social media platforms. These organizations 
and peer support groups have allowed geographically diverse survivors of SCAD to connect 
with, to provide support to, and to receive support from peers.
EVALUATION AND MANAGEMENT OF CHEST PAIN SYNDROMES AFTER 
SCAD
The collective experience suggests that chest pain is extremely common after SCAD, 
occurring in more than half of outpatients.86,214 It is unknown whether chest pain is more 
common in patients after SCAD than in sex- and age-matched control subjects after 
atherosclerotic MI. The symptoms can challenge both patient and clinician and often result 
in frequent evaluations, diagnostic testing, and substantial psychological burden. Post-SCAD 
symptoms range from acute chest pain that is reminiscent of the patient’s SCAD presenting 
symptoms, typical or atypical angina, to clearly noncardiac, but concerning, symptoms.
The differential diagnosis for patients who have chest pain syndrome after SCAD is similar 
to that in patients after ACS, with the additional consideration of extension or recurrent 
coronary dissection (Figure 9). An initial careful history and physical examination are 
critical. The clinician should be vigilant for signs and symptoms of instent restenosis or 
recurrent SCAD. The presence of noncardiac pain should be a diagnosis of exclusion, but 
differentiating chest wall and musculoskeletal discomfort on the basis of reproducibility on 
physical examination can be reassuring. If patients have more classic exertional symptoms, 
then diagnostic testing such as an exercise treadmill test, stress echocardiography, or 
perfusion imaging can be performed.25 If the study results are abnormal, coronary 
angiography, CCTA, and initial medical therapy are options, depending on the severity of 
symptoms and degree of ischemia. Alternatively, if symptoms are stable or there is evidence 
of a noncardiac cause of the discomfort, patients can receive close monitoring for cardiac 
symptoms, reassessment, and guidance on activities during cardiac rehabilitation.138,213
Frequently after SCAD, patients experience nitrate-responsive chest pain, often at rest or 
with mental stress, but have no inducible ischemia with even high levels of exercise. 
Premenopausal women may report chest pain at variable but predictable times of their 
menstrual cycle.241 One hypothesis is that this is a result of enhanced coronary vasomotion 
and abnormal endothelial function or persistent microvascular dysfunction. Clinically, some 
of these patients respond to empirical use of long-acting nitrates or calcium channel 
blockers, either daily or during days of the month when they are predictably symptomatic. 
Although the use of these agents may be limited by adverse effects of hypotension or 
headaches, empirical therapy may be considered if the patient’s symptoms are relieved with 
short-acting nitrates. The frequency and severity of chest pain have been observed to 
decrease over time, a result that may reflect vessel healing or resolution of stress, anxiety, 
and depression.
CORONARY ARTERY ASSESSMENT AFTER SCAD
After the acute presentation, diagnosis, and in-hospital management of SCAD, there may be 
reasons to reimage the dissected coronary arteries. Given the potential risks of iatrogenic 
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dissections in patients with SCAD, repeat coronary angiography should be performed only 
when benefits may outweigh the potential risks, such as in patients with recurrent symptoms, 
abnormal functional tests, unclear cause of coronary stenosis (to assess for angiographic 
healing to help differentiate SCAD from other coronary disease), or high-risk anatomy (eg, 
left main, proximal, or multivessel dissection, in which residual dissections may benefit 
from revascularization for high ischemic burden). The role of CCTA for reassessment after 
SCAD was discussed previously. A summary of coronary imaging in the evaluation of post-
SCAD chest pain in the nonacute setting is outlined in Figure 9.
PREGNANCY, CONTRACEPTION, AND HORMONE USE AFTER SCAD
Given the concerns for possible recurrent SCAD on re-exposure to the physical, hormonal, 
and potentially emotionally stressful conditions present during pregnancy and the 
postpartum period and the current lack of secondary prevention strategies, many clinicians 
recommend against subsequent pregnancy in women after SCAD, although there are few 
data to support this potentially life-changing recommendation. In the only published series 
to date examining subsequent pregnancy after a previous SCAD event, 8 patients were 
followed up for a median of 36 months (inter-quartile range, 24±70 months). One of the 8 
patients experienced recurrent SCAD after delivery, presenting with ST-segment–elevation 
MI and ultimately requiring CABG because of unsuccessful PCI.242 Given the potential risk 
of recurrent SCAD in a subsequent pregnancy and the accumulating evidence that 
pregnancy-associated SCAD can result in worse outcomes,85,90,96 clinicians should carefully 
counsel any patient contemplating pregnancy of the potential risk. Included in the 
consideration are risks associated with medication use, functional status, and concomitant 
myocardial or valvular dysfunction.
Patients who elect to attempt pregnancy after SCAD should be referred to tertiary medical 
centers for preconception assessment and counseling, and those who become pregnant 
without such consultation should seek early postconception evaluation and close follow-up 
by a multidisciplinary team that includes maternal-fetal medicine specialists, cardiologists 
with experience managing SCAD, and obstetric anesthesiologists. Patients should be 
counseled on the potential increased risk of dissection and complications during the 
pregnancy. The management of these patients should include careful review of their medical 
regimen and adjustment or removal of medications that are unsafe or not recommended in 
pregnancy (angiotensin-converting enzyme inhibitors, atenolol, statins) and cardiac testing, 
including baseline electrocardiography and echocardiography.
Careful planning of the labor and delivery process and close postpartum care are essential.
90,209
 Mode of delivery should be individualized, taking into account LV function, vascular 
comorbidities such as FMD and vascular Ehlers-Danlos syndrome, and obstetric variables, 
with a goal of minimizing intrapartum cardiovascular stress. Considerations include early 
epidural placement, left lateral decubitus positioning, and treatment of hypertension. 
Although there is insufficient evidence to guide optimal mode of delivery in patients with 
SCAD, most cardiologists and maternal-fetal medicine specialists advocate for vaginal 
delivery, similar to recommendations for women with systemic vascular or connective tissue 
disorders. Other factors are the increased risk of hemorrhage, infection, thrombosis, and 
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hemodynamic fluctuations with cesarean delivery in patients with cardiovascular disease.
197,243,244
 Minimizing maternal effort during vaginal delivery, with passive descent in the 
second stage of labor and delayed Valsalva effort, is advised; operative vaginal delivery or 
cesarean delivery is used secondarily.195,197 Because SCAD occurs primarily in women and 
is associated with pregnancy, there is a presumed pathophysiological association with female 
sex hormones, although the precise relationship remains unclear. Although there is no direct 
evidence linking hormonal contraception with recurrent SCAD, exogenous exposure to 
systemically absorbed hormones, including estrogen and progesterone for contraceptive and 
post-menopausal therapy, is usually avoided if possible, and they are used only if the 
nonhormonal options have been considered and the benefits of HT outweigh potential risks.8 
Preferred methods of contraception include vasectomy for the male partners of patients with 
SCAD, tubal ligation (preferably performed once dual-antiplatelet therapy has been 
stopped), and intrauterine devices with local delivery of progestin (levonorgestrel 20 μg/d). 
Traditional or copper-containing intrauterine devices may be associated with increased 
cramping and menorrhagia, particularly in women receiving aspirin or dual-antiplatelet 
therapy.
Many female patients with SCAD are faced with decisions about management of menopause 
and post-menopausal HT. Compared with oral and transdermal hormonal contraceptives, 
postmenopausal HT formulations have substantially lower levels of estrogen and 
progesterone and have a lower risk of thrombosis, but concerns include the uncertain effects 
of HT on SCAD incidence and recurrence and the absence of safety data available to guide 
the initiation or continuation of HT specific to SCAD. Therefore, it is necessary to 
individualize recommendations through the use of relevant consensus statements, guidelines,
245
 and indications for use and to take into account patient preferences, known and perceived 
risks and benefits, and symptom severity while recognizing that the risks of HT differ 
depending on type, dose, duration of use, route of administration, timing of initiation, and 
whether a progesterone is used.
Patients who experience SCAD while receiving HT should have their indications for HT 
reassessed, and unless there are compelling reasons to continue, HT should be discontinued. 
Indications for initiation of exogenous HT include premature and early surgical menopause, 
severe vasomotor symptoms that cannot be managed with lifestyle or nonhormonal 
treatments, and local treatment of genitourinary syndrome of menopause.245 If severe 
vasomotor symptoms or genitourinary syndrome of menopause develop at menopause or 
return on stopping the use of HT, consideration of the use of HT can be made in 
collaboration with cardiovascular and menopause specialists. The appropriate, often lowest, 
effective dose of systemic HT consistent with treatment goals that provides benefits and 
minimizes risks for the patient should be the therapeutic goal. Locally applied vaginal 
estrogen is generally thought to be safe because there is minimal systemic absorption. 
Patients with cardiovascular disease are typically advised to use a transdermal systemic 
agent to minimize activation of thrombotic factors and effects on lipids.246 The indications, 
benefits, and risks of continuing or discontinuing use of HT should be reviewed periodically.
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MANAGEMENT OF ABNORMAL UTERINE BLEEDING AFTER SCAD
Antiplatelet therapy is frequently prescribed after SCAD, and many proposed therapeutic 
regimens call for the use of aspirin and short-term use of clopidogrel after PCI. In this 
setting, many women of reproductive age receiving dual-antiplatelet therapy report abnormal 
uterine bleeding. The most common type related to this therapy is heavy menstrual bleeding, 
defined as cyclic bleeding that is heavy for prolonged periods.247 Chronic or heavy bleeding 
can result in anemia and pose a substantial disruption to activities of daily living. An 
important first step is to reassess the indication for ongoing antiplatelet therapy and to 
discontinue its use if appropriate.
When chronic heavy menstrual bleeding develops in women receiving antiplatelet therapy 
after SCAD, especially if it is severe, they often require intervention to manage bleeding. 
Patients with hemodynamic instability or bleeding that saturates a large pad or tampon 
hourly for at least 4 hours usually warrant urgent evaluation, and all reproductive-age 
women with abnormal uterine bleeding should be tested for pregnancy. In women without 
cardiovascular disease, medical management with HT is usually sufficient and the first-line 
approach to control most heavy menstrual bleeding, but this approach is relatively 
contraindicated in SCAD, and careful clinical judgment is required. Other nonhormonal, 
noncontraceptive options for treating abnormal uterine bleeding such as nonsteroidal anti-
inflammatory drugs and tranexamic acid should generally be avoided in women with SCAD 
given their association with MI and thrombosis.248–250
Among medical therapies for heavy menstrual bleeding, progestin-eluting intrauterine 
devices such as the levonorgestrel 20 μg/d–releasing device may be useful for controlling 
bleeding and protect against pregnancy.251,252 Systemic progesterone levels may increase 
minimally with these intrauterine devices, but the main effect is at the en-dometrial level. 
The levonorgestrel 20 μg/d–releasing device is the most effective approach (comparable to 
the efficacy of endometrial ablation), resulting in 71% to 95% reduction in menstrual blood 
loss, and is the only progestin intrauterine device that has been evaluated for treatment of 
abnormal uterine bleeding. In 2013, a lower-dose progestin device (releasing levonorgestrel 
14 μg/d) became available253 and, if shown effective for management of abnormal uterine 
bleeding, may afford advantages for patients with SCAD in light of lower hormonal 
absorption. Although there are theoretical safety concerns, cyclic oral progestin treatment 
has been found to reduce bleeding by 87%252,254,255 and generally results in irregular 
bleeding and often reduction of menses to only light bleeding. In hemodynamically unstable 
women in whom bleeding is not controlled, high-dose oral or injectable progestin-only 
medications may be considered for the short term.
Because patients with SCAD are generally advised to avoid both pregnancy and exogenous 
hormones and because the long-term efficacy of conservative surgical treatment for heavy 
menstrual bleeding such as second-generation endometrial ablation techniques (thermal 
balloon, microwave, radiofrequency) is greater than that of oral medical treatment,256 these 
interventions may be considered in the management of heavy menstrual bleeding after 
SCAD. Advantages of these ablative procedures include effectiveness in managing bleeding, 
reduction of pregnancy risk, and the ability to perform the procedure on patients without 
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discontinuation of antiplatelet or anticoagulation therapy. Other surgical options to control 
abnormal uterine bleeding are used primarily for women with structural abnormalities such 
as polyps and fibroids. Balloon tamponade (30-mL balloon catheter) has been described as 
an additional mechanical option to control acute bleeding in women who do not respond to 
HT.
SCREENING FOR SCAD-ASSOCIATED CONDITIONS
In the majority of patients, SCAD is not an isolated event but is reflective of an underlying 
vascular, genetic, or as-yet undetected condition. To help determine appropriate follow-up 
evaluations, practitioners caring for patients with SCAD should obtain a careful history, 
including a detailed review of systems and personal and family history of SCAD-associated 
symptoms and conditions. A list of screening questions to consider in the evaluation of the 
patient with SCAD is given in Table 4.
DIAGNOSIS OF SCAD-ASSOCIATED EXTRACORONARY ARTERIOPATHIES
FMD and other extracoronary vascular abnormalities are strongly associated with 
SCAD13,34,257 and have the potential to affect management and inform prognosis. The 
rationale for extracoronary vascular screening is to diagnose underlying associated 
conditions such as FMD, which may point to a potential cause of SCAD, and to identify 
other vascular abnormalities such as aneurysms or dissections that may require additional 
evaluation, management, or longitudinal follow-up.75 Accordingly, all patients who have 
experienced SCAD should undergo a complete vascular physical examination with palpation 
and auscultation of the abdominal aorta, cervical carotid arteries, and peripheral arteries of 
the upper and lower extremities. A diminished pulse, side-to-side asymmetry, or bruit may 
be indicative of stenotic or dissected arteries, and widened or bounding pulse may be 
indicative of aneurysmal disease. In the US Registry for FMD, the presence of an epigastric 
or flank bruit had low sensitivity for the detection of renal FMD (24.0%); however, the 
specificity and positive predictive value were 93.3% and 92.6%, respectively.257 Thus, the 
absence of a bruit does not sufficiently rule out arterial disease, but its presence should 
heighten suspicion of an underlying arteriopathy.
Given the high coprevalence of FMD, aneurysm, and other extracoronary vascular 
abnormalities among patients with SCAD,13,34,70,76,258,259 vascular imaging from the brain 
to pelvis should be considered in all patients, similar to current practice for FMD.70,71 
According to the US Registry for FMD,257 the most commonly involved vascular beds are 
the renal arteries (79.7%), followed by the extracranial carotid arteries (74.3%).70,257 Recent 
imaging series among patients with SCAD reported the presence of intracranial aneurysm in 
14% to 23%.13,75 In addition, several conditions associated with an increased prevalence of 
unruptured intracranial aneurysms overlap with those associated with SCAD, including 
FMD, vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome, and polycystic kidney 
disease.257,260–264 The ultimate goal of vascular screening is the detection of high-risk 
aneurysms or extracoronary abnormalities requiring treatment in order to avoid aneurysm 
rupture and other complications associated with substantial morbidity and mortality.265–268 
Screening for FMD and other extracoronary vascular abnormalities must include patient 
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counseling for the possible outcomes, including a false-negative result (false reassurance), a 
false-positive result (and the risk of further testing), a true-positive result with advice for 
conservative management (and the potential for anxiety at the knowledge of harboring an 
aneurysm or dissection), and a true-positive result with advice for treatment. In the case of a 
true-positive result, there is a risk of treatment-associated harm (iatrogenic dissection, 
stroke, aneurysmal rupture, and adverse effects of contrast agent).
Long-term management of FMD and other extravascular abnormalities is beyond the scope 
of this statement, and we suggest using the approaches outlined in condition-specific 
American Heart Association guidelines and scientific statements.70,226,268
Angiography
The standard imaging method for diagnosing FMD is catheter-based angiography given its 
superior spatial resolution (<0.1 mm), and it is the definitive test to diagnose cases that are 
equivocal on noninvasive imaging.70 In patients undergoing coronary angiography to 
diagnose SCAD, additional nonselective or selective renal and iliac artery catheter-based 
angiography can be done in the same setting to assess for FMD. Similarly, for brain 
imaging, 2-dimensional digital subtraction angiography has historically been the reference 
standard for in vivo diagnosis of intracranial and cervical FMD and aneurysms, but the 
superior detection of small aneurysms or subtle FMD compared with noninvasive testing 
may not offer a clinically relevant advantage. Given this, as well as the low, but important, 
rate of procedural complications, digital subtraction angiography is not generally used as an 
initial method for cerebrovascular screening purposes but may be appropriate when the 
diagnosis is still uncertain after noninvasive imaging or when intervention is contemplated.70
Computed Tomography Angiography
In patients undergoing noninvasive imaging, the higher resolution of computed tomography 
compared with that of magnetic resonance imaging and ultrasonography and the ease of 
imaging across multiple vascular territories in a single scan may improve detection of the 
vascular abnormalities that are often found in SCAD.76 Notably, the FMD findings in 
patients with SCAD may be subtle and can be missed if not specifically sought. Regardless 
of the imaging method chosen, careful and focused image interpretation is critical. Multiple 
reconstruction formats, including multiplanar reformatted images, shaded surface display, 
and maximum-intensity projections, are necessary to adequately review for changes of 
FMD.70,269 For the detection of brain aneurysms, multirow detector computed tomography 
angiography is generally the preferred noninvasive imaging method because it provides 
detailed evaluation of the extracranial carotid, vertebral, and intracranial arteries for 
potential aneurysms.70,270,271 The sensitivity for aneurysms <3 mm is 82%.271 Advances in 
computed tomography technology such as third-generation dual-source systems continue to 
drive down radiation exposure and further shorten scanning time while preserving or 
improving image resolution. Novel protocols to image multiple vascular beds in a single 
diagnostic session can facilitate patient convenience and diagnostic accuracy over magnetic 
resonance angiography.75
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Magnetic Resonance Angiography
Magnetic resonance angiography has lower spatial resolution than computed tomography 
angiography for FMD diagnosis,12,272 but newer magnetic resonance angiography can take 
advantage of volume rendering and strong magnets (3.0 T) that have increased the sensitivity 
for detection of aneurysms, despite the potential for false-negative and false-positive results.
273
 Benefits of magnetic resonance angiography include the absence of radiation, highly 
sensitive imaging of the brain parenchyma, and no requirement for contrast agent. The 
technique is limited by contraindications to magnetic resonance imaging (implanted metal, 
older pacemakers) and long scanning times that can lead to a higher likelihood of motion 
artifact degrading the image.
Duplex Ultrasonography
Duplex ultrasonography for the diagnosis of FMD is challenged by the need for highly 
skilled technicians and oversight by interpreting physicians.70 Given the lower sensitivity of 
duplex ultrasonography compared with that of computed tomography angiography or 
magnetic resonance angiography for FMD and other arteriopathies, this method has largely 
been replaced by computed tomography angiography or magnetic resonance angiography in 
most institutions for screening in the SCAD population.
Radiation Exposure: Special Considerations for Young and Female Patients
The disadvantage of angiographic or computed tomographic approaches to screening for 
extracoronary abnormalities and coronary imaging is the exposure to ionizing radiation. 
Given that the majority of SCAD occurs in young patients and that imaging plays a critical 
role in diagnosis and management, a discussion of radiation exposure is highly relevant. For 
women, the lifetime attributable risk of cancer is estimated at 2- to 4-fold greater for an 
exposure occurring at 20 versus 60 years of age compared with the risk in men.274 Because 
these young patients have a longer potential lifespan and are at risk of recurrent SCAD 
events and other conditions requiring imaging, there is an increased probability for multiple 
imaging tests, repeated procedures, and multiple healthcare providers being involved in their 
care. Cardiac imaging studies used in the evaluation of SCAD requiring ionizing radiation 
(invasive angiography and CCTA, stress myocardial perfusion imaging with positron 
emission tomography, and single-photon emission computed tomography) should be 
performed only after individualized assessment of risks and benefits. Both technological and 
operator radiation dose–reduction strategies should be used.275,276 Once systemic 
arteriopathy is diagnosed or an extracoronary dissection or aneurysm is identified that 
requires longitudinal follow-up, subsequent use of alternative imaging methods that do not 
expose the patient to ionizing radiation (eg, magnetic resonance angiography, duplex 
ultrasonography) should be considered.70,76 Particular efforts should be made to limit both 
patient and offspring radiation and contrast agent exposure in pregnant or lactating patients 
with SCAD, in whom non-emergency imaging should be deferred.199
ROLE OF GENETIC EVALUATION
The yield from routine genetic testing in patients with SCAD, especially among those 
without a suggestive personal or family history or physical examination of an inherited 
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systemic arteriopathy or connective tissue disorder, has been shown to be low,107 and in the 
absence of a suggestive history or physical examination (Table 4), routine genetic testing 
after SCAD is not currently advised. Similarly, in patients with FMD, screening for variants 
in known arteriopathy-causing genes also seems to be of low yield.121,122 However, given 
the known association of SCAD with several inherited arteriopathies, referral to a specialist 
in medical genetics for further evaluation should be considered to aid in decision making for 
formal genetic assessment if an underlying systemic arteriopathy or connective tissue 
disorder is suspected in SCAD survivors. Patients with pregnancy-associated SCAD should 
also be considered for this evaluation because an underlying arteriopathy may be triggered 
by the hemodynamic and hormonal changes of pregnancy. Although the prevalence of these 
disorders is low, the diagnosis of a systemic arteriopathy may influence recommendations 
for frequency of vascular screening, timing of surgical intervention for aneurysms, or 
assessment of risk of pregnancy in the case of vascular Ehler-Danlos syndrome. This 
information can also guide screening in first-degree family members to determine their risk 
of aneurysm or dissection and need for clinical screening.
Formal medical genetics consultation, and testing if indicated, should be performed at a 
referral center with experience in genetically mediated arteriopathies and availability of 
medical genetics specialists.277 Given the complex financial, insurance, familial, and social 
issues surrounding genetic testing, genetic counseling is paramount before mutation 
screening.277 During the clinical evaluation for a genetically mediated arteriopathy, family 
history is assessed with a 3-generation pedigree, personal history, and examination for 
features characteristic of connective tissue disorders, including features of Marfan syndrome 
and other disorders caused by transforming growth factor-β pathway gene mutations, as 
reviewed in the Inheritance and Genetics section. Mar-fan syndrome and neurofibromatosis 
may be diagnosed clinically.278,279 Clinical findings of polycystic kidney disease should 
prompt an evaluation, which may include gene testing in some cases.
When findings suggestive of an inherited disorder are present, sequencing of a panel of 
genes inclusive of inherited arteriopathies (eg, TGFBR1, TGFBR2, COL3A1, FBN1, 
ACTA2, SMAD3, PLOD1, and COL5A1) should be considered an efficient approach to 
evaluate genetically mediated vascular disease. The history and physical examination may 
be unrevealing in vascular Ehlers-Danlos syndrome, and thus, the threshold for COL3A1 
mutation testing may be lower.
Given the rapid expansion of identified genes for aortopathies, clinical genome sequencing 
(focused on whole genome or exome) may provide a single source of genetic data in which 
queries may be performed as new findings emerge. However, given the current lack of data 
showing defined, specific genetic causes for SCAD and the sporadic nature of the disease, 
routine whole-genome or exome sequencing is not currently recommended. In the absence 
of a confirmed diagnosis of a heritable arteriopathy or connective tissue disorder, clinical 
screening in first-degree family members of patients who experienced SCAD is not clearly 
indicated.
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SCAD PROGNOSIS AND RECURRENCE RISK
The short- and long-term prognosis and risks of SCAD recurrence are highly relevant and of 
concern to both patients and their providers. After hospital dismissal, intermediate and long-
term adverse cardiovascular events after SCAD are relatively common and include chest 
pain, depression, anxiety, and major adverse cardiac events such as recurrent MI, recurrent 
SCAD, unanticipated revascularization, congestive heart failure, stroke, and death. At an 
intermediate-term follow-up of 2 to 3 years, major adverse cardiac events were reported in 
10% to 30% of cases, mostly caused by recurrent MI from recurrent SCAD, reported in 15% 
to 22% of patients.11,13,193 At longer-term follow-up, major adverse cardiac events were 
reported in 15% to 37% at 5 to 7 years, and the Kaplan-Meier–estimated rate of major 
adverse cardiac events is ≈50% at 10 years.8,10,13 These longer-term major adverse cardiac 
events are related predominantly to recurrent SCAD, which was estimated at up to 30% at 4 
to 10 years of follow-up in different series.8,11,13,19
The reported rates of a recurrent episode of SCAD vary considerably in the literature (0%–
37%),8–11,13,30,280 likely representing differences in study design, duration of follow-up, and 
definition of recurrence. Historically, the term recurrent SCAD has been used relatively 
interchangeably to describe 2 distinct forms of dissection: extension of the index dissection 
in the acute phase resulting from expansion of the IMH of the unhealed SCAD lesion and de 
novo dissection unrelated to the index dissection, affecting different coronary artery 
segments and occurring later (>30 days) and remote from the index event.8,11,13,19,281 Given 
the disparate features and pathophysiology of extension of dissection and de novo recurrent 
dissection, the term recurrent SCAD should be limited to describe subsequent de novo 
SCAD.
When reports of recurrent SCAD are limited to subsequent de novo dissections, incident 
recurrent SCAD rates are more consistent, and SCAD recurs in previously unaffected 
arteries 77% to 100% of the time.8,11,13,19,281 In the Mayo Clinic series, SCAD recurred in 
17% of patients (15 of 87) at a median time to the second episode of 2.8 years, and the 10-
year Kaplan-Meier–estimated risk of recurrence was 29.4%.8 In the updated series by Eleid 
et al83 with 246 patients, the reported rate was 16% over a median duration of 1.7 years. In 
the Japanese series, recurrent SCAD was reported in 19% of patients (14 of 63) at a median 
duration of 42 days.11 In the 168-patient Vancouver series, recurrent SCAD was reported in 
13% of patients (22 of 168).6 In the updated 310-patient Vancouver cohort, recurrent SCAD 
occurred in 11% of patients (34 of 310); in all patients, new coronary artery segments were 
affected, and the recurrence was 30 days (median, 3.6 years) after the index SCAD.281
Identification of risk markers or risk factors for recurrent SCAD has been and remains an 
important clinical goal. Small sample size of studies has been a limitation, and to date, only 
severe coronary tortuosity has been identified as a risk factor for recurrence, with recurrence 
most likely to occur in a segment of tortuosity.83 Whether tortuosity itself confers a direct 
pathophysiological risk or is simply a marker of a high-risk patient phenotype remains 
uncertain. Coronary tortuosity was also shown to be a coronary manifestation of FMD12,82 
and thus may be a confounder for the presence and strong association with FMD. 
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Furthermore, the presence of FMD itself has not been identified as a predictor of recurrent 
SCAD.83,193
RESEARCH PRIORITIES AND CALL TO ACTION
SCAD is an important cause of ACS in otherwise healthy young and middle-aged 
individuals, particularly women without traditional cardiovascular risk factors. It is 
frequently underdiagnosed or misdiagnosed and can potentially result in substantial 
morbidity and mortality; a heightened suspicion for SCAD is required for accurate diagnosis 
and treatment. Despite increased recognition of the condition by the medical community and 
patients, large gaps in knowledge must be addressed to provide the best outcomes. It should 
be acknowledged that only recently have there been even limited prospective studies, and 
most available data are retrospective and observational. The findings are limited by referral 
bias and survivor bias, both of which may serve to overestimate recurrence risk. Conversely, 
the well-recognized sex bias in pursuing cardiac investigations in young women presenting 
with chest pain, together with known challenges in diagnosing SCAD even when 
investigations are undertaken, may serve to underestimate recurrence risk. Future larger-
scale prospective and epidemiological studies will help further our understanding of the 
demographic, treatment, and anatomic factors associated with recurrence and allow more 
accurate prediction and ultimate prevention of recurrent SCAD.
The writing committee has classified research priorities into the areas of epidemiology, 
pathogenesis, diagnosis, and treatment (Table 5), each with key questions intended to spur 
collaborative research and advances in treatment for this disease. SCAD is an important 
cause of MI, particularly in young women. Although several key questions have yet to be 
answered, this writing group hopes that this document increases the awareness of SCAD 
among physicians and other healthcare providers and thus improves the recognition and 
management of SCAD. This awareness must then initiate collaborative research efforts to 
help understand the natural history of SCAD and to develop therapies to prevent SCAD 
complications and recurrence. We applaud the efforts of SCAD survivor–led initiatives, 
which have sparked collaboration and research thus far. We also call on the medical 
community to continue efforts to drive progress in this disease and to educate fellow 
physicians about SCAD. We hope that this inaugural American Heart Association scientific 
statement on SCAD becomes the catalyst for a call to action among the medical and patient 
communities.
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Figure 1. Cross-sectional views of the coronary artery
A, Normal coronary artery. B, Coronary artery with intramural hematoma. C, Coronary 
artery with intimal tear. Spontaneous coronary artery dissection is characterized by the 
spontaneous formation of an intramural hematoma, which can lead to compression of the 
true lumen and myocardial infarction. An intimal tear may be present. Created by and used 
with permission from Dominic Doyle, MA.
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Figure 2. Pathological appearance of spontaneous coronary artery dissection
Histological (A) and pathological (B) appearances show compression or obliteration of the 
true lumen (TL; arrows) by hematoma within the false lumen (FL). Used with permission 
from Mary N. Sheppard, Department of Cardiovascular Pathology, St. George Medical 
School, London, UK.
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Figure 3. String-of-beads appearance of multifocal fibromuscular dysplasia (FMD)
Selective angiography of the right renal artery (A) and computed tomography angiography 
of the carotid (B) and renal (C) arteries. B and C are from the same patient. Findings of 
FMD in the right renal artery are more subtle (C, arrow) but suggest FMD given obvious 
beading elsewhere (B, red arrow). Also present in the bilateral internal carotid arteries is 
aneurysmal dilatation (aneurysm vs pseudoaneurysm; B, white arrows).
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Figure 4. Frequency of presenting symptoms of acute spontaneous coronary artery dissection
VF indicates ventricular fibrillation; VT, ventricular tachycardia. Adapted from Luong et 
al132 with permission. Copyright © 2017, Wiley Periodicals, Inc.
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Figure 5. Angiographic features of spontaneous coronary artery dissection
A, Type 1, multiple radiolucent lumens (arrow) or arterial wall contrast staining. B, Type 2, 
diffuse stenosis that can be of varying severity and length (dissection starting from arrow). 
C, Type 3: focal or tubular stenosis (arrow), usually <20 mm in length, that mimics 
atherosclerosis. Intracoronary imaging should be performed to confirm the presence of 
intramural hematoma or multiple lumens. D, Optical coherence tomography in type 3 (C) 
shows intramural hematoma (asterisk).
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Figure 6. Intracoronary imaging for spontaneous coronary artery dissection
A, Optical coherence tomography shows intimal dissection (solid arrow) and intramural 
hematoma (asterisk). B, Intravascular ultrasonography shows intramural hematoma (dotted 
arrow) compressing the true lumen (asterisk).
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Figure 7. Algorithm for diagnosis of spontaneous coronary artery dissection (SCAD) in the 
setting of acute coronary syndrome
CT indicates computed tomography; CTA, computed tomography angiography; FMD, 
fibromuscular dysplasia; IC, intracoronary; IVUS, intravascular ultrasonography; MRA, 
magnetic resonance angiography; and OCT, optical coherence tomography.
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Figure 8. Algorithm for management of acute spontaneous coronary artery dissection
CABG indicates coronary artery bypass grafting; PCI, percutaneous coronary intervention; 
and Rx, management. aLeft main or proximal 2-vessel coronary artery dissection.
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Figure 9. Evaluation and management of chest pain after spontaneous coronary artery dissection 
(SCAD).157,170
aCurrent guidelines.135 bHigh-risk anatomy indicates SCAD affecting the left main or 2 
proximal coronary arteries. cMedical management for post-SCAD chest pain (CP) without 
obstructive disease: long-acting nitrates, calcium channel blockers, or ranolazine. ACS 
indicates acute coronary syndrome; CA, coronary angiography; CAD, coronary artery 
disease; CCTA, coronary computed tomography angiography; CMR, cardiac magnetic 
resonance; DDx, differential diagnosis; and echo, echocardiography.
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Table 2
Conditions and Factors Associated With SCAD
Associated Condition or Factor
Reported Prevalence in 
Cohort Studies, %
Fibromuscular dysplasia 25–8613,29,33,34
Pregnancy 2–88,9,13,33
Multiparity (≥4 births) 8.9–1013,33
Inherited arteriopathy and connective tissue disorder (see Table 4) 1.2–3.08,13
 Marfan syndrome, Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, α1- antitrypsin deficiency, 
polycystic kidney disease
Exogenous hormones 10.7–12.68,13
 Oral contraceptives, postmenopausal therapy, infertility treatments, testosterone, corticosteroids
Systemic inflammatory disease <1–8.99,13
 Systemic lupus erythematosus, Crohn disease, ulcerative colitis, polyarteritis nodosa, sarcoidosis, Churg-
Strauss syndrome, Wegener granulomatosis, rheumatoid arthritis, Kawasaki disease, celiac disease
Migraine headache NR
Coronary artery spasm NR
Precipitating factors >50% Patients recall a 
precipitating factor13
 Intense exercise (isometric or aerobic)
 Intense Valsalva
 Retching, vomiting, bowel movement, coughing, lifting heavy objects
 Intense emotional stress
 Labor and delivery
 Recreational drugs (cocaine, methamphetamines)
 Exogenous hormones/hormone modulators β-hCG injections, corticosteroid injections, clomiphene
hCG indicates human chorionic gonadotropin; NR, not reported; and SCAD, spontaneous coronary artery dissection.
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Table 4
Screening Questions for SCAD-Associated Arteriopathies and Connective Tissue Disorders
Personal history (Have you ever been diagnosed with or experienced any of the following?)
 Early-onset hypertension
 Stroke or transient ischemic attack
 Pulsatile tinnitus
 Migraine headaches
 Renal infarction
 Subarachnoid hemorrhage
 Aneurysm (aortic, peripheral, brain)
 Dissection (aortic, peripheral)
 Rupture of hollow organs (intestinal, bladder, uterine)
 Pneumothorax
 Tendon or muscle rupture
 Joint dislocation
 Talipes equinovarus (clubfoot)
 Umbilical or inguinal hernia
 Scoliosis or pectus deformity
 Pregnancy complications (cervical incompetence, hemorrhage, uterine prolapse, hypertension)
 Poor wound healing
 Ectopia lentis
 Myopia
 Detached retina, early glaucoma, or early cataracts
 Tall stature
 Abnormality of cardiac valve (bicuspid aortic valve, mitral valve prolapse)
 Systemic inflammatory disease
Family history (Does anyone in your family have any of the following?)
 Dissection (coronary, aortic, peripheral)
 Inherited arteriopathy or connective tissue disorder (eg, vascular Ehlers-
 Danlos syndrome, Marfan syndrome, Loeys-Dietz syndrome)
Fibromuscular dysplasia
Aneurysm (aortic, peripheral, brain)
 Early stroke, early myocardial infarction, sudden cardiac death
Review of systems (Are you currently experiencing any of the following?)
 Headaches
 Pulsatile tinnitus
 Postprandial abdominal pain
 Flank pain
 Claudication
 Easy bruising
 Joint hypermobility or laxity
SCAD indicates spontaneous coronary artery dissection.
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Table 5
Research Priorities and Key Questions in SCAD
Epidemiology
 What is the prevalence of SCAD in the general population?
 Are there sex differences in the cause, presentation, diagnosis, and treatment of SCAD?
 What is the recurrence rate of SCAD, and what are the determinants of recurrence?
Pathogenesis
 Are there underlying genetic, hormonal, and environmental causes of SCAD, and what are the proportionate contributions of each?
 What are the roles of physical and emotional stress and other potential triggers of SCAD?
 What is the proportionate contribution of FMD and other systemic arteriopathies to the development and recurrence of SCAD?
Diagnosis
 Under what circumstances and time frame and with what imaging method should follow-up coronary imaging be performed?
Treatment
 What are the optimal approaches for initial revascularization?
 What is the role of anticoagulation and antiplatelet therapy in SCAD immediately and after the event?
 What are appropriate physical activity guidelines after SCAD?
 What are the risks of exogenous hormone therapy and pregnancy after SCAD?
FMD indicates fibromuscular dysplasia; and SCAD, spontaneous coronary artery dissection.
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